Keith L. Brownlie

CIK: 0001518575

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CLDX

Celldex Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (2 total)

CLDX
Celldex Therapeutics, Inc.
Jun 25, 2026
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
26K shares-
CLDX
Celldex Therapeutics, Inc.
Jun 5, 2025
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
16.5K shares-

		Type	Shares	Price		Ownership
Jun 25, 2026	CLDX Celldex Therapeutics, Inc.	Award(A) Non-Qualified Stock Option (right to buy)	26,000	-	-	Direct
Jun 5, 2025	CLDX Celldex Therapeutics, Inc.	Award(A) Non-Qualified Stock Option (right to buy)	16,500	-	-	Direct

1-2 of 2 transactions

About Brownlie Keith L

Brownlie Keith L (SEC CIK 0001518575) files insider reports with the SEC as Director of Celldex Therapeutics, Inc. (CLDX).

Signal8 holds 2 ownership filings by Brownlie Keith L, all Form 4s, filed between Jun 9, 2025 and Jun 29, 2026. Those filings report 2 transactions, from Jun 5, 2025 to Jun 25, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Brownlie Keith L's filings is in HAMPTON, NJ.

Recent filings by Brownlie Keith L

Jun 25, 2026: Grant or award of CLDX derivative securities (Form 4, code A).
Jun 5, 2025: Grant or award of CLDX derivative securities (Form 4, code A).

Other insiders filing for Celldex Therapeutics, Inc. (CLDX)

Lawver Teri L, SVP & Chief Commercial Officer
Jimenez Freddy A., SVP & GENERAL COUNSEL
Young Diane C., SVP, CHIEF MEDICAL OFFICER
Heath-Chiozzi Margo, SVP OF REGULATORY AFFAIRS
Martin Samuel Bates, SVP AND CFO
Cavanaugh Sarah, SVP OF CORP AFFAIRS & ADMIN.

How to read Form 4 transaction codes